Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655898 · ClinicalTrials.gov registry record · Phase 1
Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04655898: Completed Phase 1 study, sponsored by Celgene.
NCT04655898 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04655898, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a clinical pharmacology study to characterize the biotransformation and excretion of \[14C\]CC-90001 and to evaluate the safety and tolerability of \[14C\]CC-90001 following a single oral dose of \[14C\]CC-90001 in healthy male subjects. Approximately 8 subjects will be enrolled into the study with a goal of 6 subjects being eligible for analysis.
Primary Outcome
Total \[14C\]-Radioactivity (RA) in whole blood, plasma, urine, and feces) will be measured via Liquid scintillation counting (LSC)
Interventions
- DRUG [14C]CC-90001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-12-16 |
| Est. Completion | 2021-03-11 |
| Phase | Phase 1 |
What the finished NCT04655898 record still lists
NCT04655898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which [14C]CC-90001 is the first listed.
NCT04655898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04655898 about?
NCT04655898 is a clinical study titled "Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects". This is a clinical pharmacology study to characterize the biotransformation and excretion of \[14C\]CC-90001 and to evaluate the safety and tolerability of \[14C\]CC-90001 following a single oral dose of \[14C\]CC-90001 in healthy male subjects. Approximately 8 subjects will be enrolled into the stu...
What is the current status of trial NCT04655898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-12-16. Estimated completion is 2021-03-11.
What interventions are being tested in trial NCT04655898?
The interventions under investigation include: [14C]CC-90001 (DRUG).
Who is sponsoring clinical trial NCT04655898?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04655898's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI